A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer

C Forbes¹*
J Wilby¹
G Richardson²
M Sculpher²
L Mather¹
R Riemsma¹

¹ NHS Centre for Reviews and Dissemination and
² Centre for Health Economics, University of York, UK

* Corresponding author

Executive summary

Health Technology Assessment 2002; Vol. 6: No. 23
Background
Ovarian cancer is the most common gynaecological cancer with an annual incidence of 21.6 per 100,000 in England and Wales. As the early stages of ovarian cancer are often asymptomatic, most cases are not detected until the advanced stages. Consequently, prognosis after diagnosis is poor with 5-year survival in the UK of only about 30%. Paclitaxel and platinum-based (cisplatin/carboplatin) therapy are currently recommended as first-line chemotherapy for ovarian cancer. However, most patients develop resistant or refractory disease eventually requiring second-line therapy. Patients may respond to rechallenge with platinum agents if the treatment-free interval is > 6 months, but an alternative is often required. Topotecan has recently been recommended as one agent to be considered for second-line therapy, and pegylated liposomal doxorubicin hydrochloride is one of three other drugs currently licensed in the UK for use in second-line therapy.

Aims of the review
To examine the clinical effectiveness and cost-effectiveness of intravenous pegylated liposomal doxorubicin hydrochloride (Caelyx®, Schering-Plough Ltd, UK; Doxil®, Alza Corporation, USA) as second-line treatment for advanced ovarian cancer after failure of first-line platinum-based therapy.

Methods

Search strategy
Twenty-three electronic databases, databases of ongoing research and Internet resources were searched from inception to June 2001, and bibliographies of retrieved articles and pharmaceutical company submissions were examined.

Inclusion/exclusion criteria
Two reviewers independently screened all titles/abstracts, and made final decisions to include/exclude studies based on full copies of articles. Any disagreements were resolved through discussion.

Data extraction and quality assessment
Data were extracted by one reviewer and checked by another. Two reviewers, using specified criteria, independently assessed the quality of the clinical effectiveness and economic studies. Any disagreements were resolved through discussion.

Analysis strategy
Due to the limited number of studies included in the review, the outcome data could not be pooled statistically. Clinical effectiveness data were discussed according to outcome. RCTs were discussed separately from Phase II studies. For time to event data, hazard ratios with 95% confidence intervals (CIs) were presented where available. For the remaining outcomes, relative risks were reported or calculated where appropriate and where sufficient data were available, and also presented as forest plots without pooled estimates. Economic data were presented as a summary and critique of the evidence. Additional analysis was undertaken to explore cost-effectiveness more fully, including assessment of assumptions underlying the submitted economic analyses using relevant experts, estimation of differential mean survival duration, presentation of cost-effectiveness acceptability curves, assessment of the sensitivity of cost-effectiveness to possible differences between therapies in health-related QoL (HRQoL) and estimation of the expected value of additional research.

Results

Included studies
Of 143 titles/abstracts screened for relevance, full copies of 53 articles were assessed for inclusion.
Eighteen published papers of two RCTs and six Phase II studies of clinical effectiveness and two economic evaluations were included. Further details of one RCT, three Phase II studies and the economic evaluations were obtained from Schering-Plough Ltd. Overall, one international multicentre RCT comparing pegylated liposomal doxorubicin hydrochloride with topotecan (trial 30-49) was used in the final assessment of clinical effectiveness; and two cost-minimisation analyses based on trial 30-49 were used in the assessment of cost-effectiveness.

Quality of clinical effectiveness data
The RCT (trial 30-49) was of reasonably good quality, although valid intention-to-treat analyses were not used to assess outcome data. The six Phase II studies had several methodological problems and were of a much weaker design. Interpretation of such data requires great caution and the evidence from these studies was, therefore, not included in the final assessment of clinical effectiveness.

Quality of economic evaluations
Trial 30-49 on which both economic analyses were based was of reasonably good quality. The economic analyses used a cost-minimisation design, which was justified by the RCT being designed to show equivalence in overall survival. However, no equivalence in HRQoL was established. Other characteristics of the economic evaluations were generally of high quality.

Assessment of clinical effectiveness
The clinical effectiveness assessment was based on the best available evidence, although this was limited to data from trial 30-49 on 474 participants. Apart from some minor exceptions, there were no significant differences between pegylated liposomal doxorubicin hydrochloride and topotecan in overall survival, median survival, response rate, median time to response, median duration of response and QoL. The only significant differences reported were identified in subgroup analyses (platinum-sensitive disease and disease without ascites), which were of questionable validity, and their relevance to a general advanced ovarian cancer patient population undergoing second-line chemotherapy is unclear. However, significant differences were observed in the incidence of adverse events. Topotecan was associated with increased haematological toxicities (including neutropenia, leukopenia, anaemia and thrombocytopenia), alopecia, nausea and vomiting. Pegylated liposomal doxorubicin hydrochloride increased the incidence of palmar–plantar erythrodysesthesia, stomatitis, mucous membrane disorders and skin rashes.

Assessment of cost-effectiveness
The analysis of costs was thorough in both economic analyses. The company submission showed a mean cost saving from the use of pegylated liposomal doxorubicin hydrochloride of £2657. The mean cost with pegylated liposomal doxorubicin hydrochloride was £9970 (95% CI, £9080 to £10,861) compared with £12,627 (95% CI, £11,527 to £13,727) with topotecan. In the analysis by Smith and colleagues,* the mean saving was US$2909 (95% CI, $779 to $3415), approximately £2078, in favour of pegylated liposomal doxorubicin hydrochloride. In both cases, the savings were largely due to lower resource use in the management of adverse events with pegylated liposomal doxorubicin hydrochloride. The fairly extensive sensitivity analysis showed the estimates of differential costs were robust to changes in key parameter values. Further analysis for this report showed that when a full probabilistic cost-effectiveness analysis was undertaken and effectiveness expressed in terms of mean survival duration, there was a high probability that pegylated liposomal doxorubicin hydrochloride is more cost-effective (70–80%). However, the possible differences in HRQoL between the two therapies, reflecting differences in adverse events, may produce quite different cost-effectiveness results when effectiveness is expressed in terms of quality-adjusted life-years (QALYs) – a preferable measure when both length of life and QoL are potentially influenced. Therefore, although pegylated liposomal doxorubicin hydrochloride is very likely to have lower costs than topotecan, its overall cost-effectiveness is unclear.

Conclusions
The main results of this review suggested that there is little RCT evidence for assessment of the effectiveness of pegylated liposomal doxorubicin hydrochloride as second-line therapy for advanced ovarian cancer. Data from only one RCT was included in the final assessment of clinical effectiveness, and only two economic evaluations relevant to the UK NHS were identified and included in the cost-effectiveness assessment.

The evidence suggested that there were no differences between pegylated liposomal doxorubicin hydrochloride and topotecan in the main clinical outcomes. However, significant differences were
observed in the incidence of adverse events. The clinical significance of these findings was not discussed. Overall, the clinical effects of pegylated liposomal doxorubicin hydrochloride could at best be described as modest, however, the only other comparator considered in this review offered no real advantages. If anything, pegylated liposomal doxorubicin hydrochloride offered possible clinical advantages over topotecan due to fewer adverse events.

Based on existing data, pegylated liposomal doxorubicin hydrochloride is less costly than topotecan. When effectiveness was based on survival duration, pegylated liposomal doxorubicin hydrochloride had a high probability of being cost-effective. However, differences between the two therapies are likely to exist in overall HRQoL, which, when expressed in terms of QALYs, could alter these cost-effectiveness results markedly.

**Recommendations for research**

To provide a clearer picture of clinical effectiveness, further good quality RCTs comparing pegylated liposomal doxorubicin hydrochloride with other licensed and potentially useful (soon to be licensed) second-line chemotherapy agents for ovarian cancer are needed. Such studies should also generate data for cost-effectiveness analysis – the economic results presented here suggest a potentially high value of additional information from further research. At present, it is difficult to make choices between pegylated liposomal doxorubicin hydrochloride and other drugs for second-line ovarian cancer treatment without such direct comparisons.

In view of the timescale required to conduct good quality RCTs and economic evaluations, and the fact that no such ongoing studies were identified, it seems reasonable not to update the current review until findings from such evaluations are available.

**Reference**


**Publication**

How to obtain copies of this and other HTA Programme reports

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.ncchta.org).

Also, a fully searchable CD-ROM containing the full text of all HTA monographs is available from the NCCHTA offices or via the HTA website. The CD-ROM is updated with the most recently published monographs every 6 months and is available free of charge to postal addresses in the UK.

In addition, printed paper copies of this report may be obtained by writing to:

The National Coordinating Centre for Health Technology Assessment, Mailpoint 728, Boldrewood, University of Southampton, Southampton, SO16 7PX, UK.

Or by faxing us at: +44 (0) 23 8059 5639

Or by emailing us at: hta@soton.ac.uk

Or by ordering from our website: http://www.ncchta.org

NHSnet: http://nww.hta.nhsweb.nhs.uk

The website also provides information about the HTA Programme and lists the membership of the various committees.
The NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.

The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.

The research reported in this monograph was funded as project number 01/20/01.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors.

Criteria for inclusion in the HTA monograph series
Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA Programme Director: Professor Kent Woods
Series Editors: Professor Andrew Stevens, Dr Ken Stein, Professor John Gabbay, Dr Ruairidh Milne and Dr Chris Hyde
Managing Editors: Sally Bailey and Sarah Llewellyn Lloyd

The editors and publisher have tried to ensure the accuracy of this report but do not accept liability for damages or losses arising from material published in this report.